CLEVELAND, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that ...
- ABO-101 was well tolerated with no serious adverse events or dose-limiting toxicities reported in the 28-days following dosing - Phase 1/2 redePHine study (NCT06839235) dose escalation ongoing with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback